Another Setback For Glitazones: Germany Withdraws Reimbursement For The Diabetes Drugs
This article was originally published in The Pink Sheet Daily
Federal joint committee decision means GSK's Avandia and Takeda's Actos no longer will be reimbursed in Germany other than in exceptional cases.
You may also be interested in...
TOKYO - Takeda Pharmaceutical's diabetes treatment Actos registered stronger-than-expected sales in the April-September period, benefiting from a price increase in the U.S. and the restricted use or market withdrawal of competitor Avandia
Rosiglitazone will be available under a Risk Evaluation and Mitigation Strategy with restricted distribution pending an independent panel's re-adjudication of CV endpoints in the much-maligned, open-label RECORD study.
Product will be taken off the market "within the next few months," EMA says as it holds an unprecedented press conference.